The "CCDC114 Gene Primary Ciliary Dyskinesia Type 20 Genetic Test" is a specialized diagnostic procedure offered by DNA Labs UAE, aimed at detecting mutations in the CCDC114 gene, which are associated with Primary Ciliary Dyskinesia (PCD) Type 20. PCD is a rare genetic disorder characterized by chronic respiratory tract infections, abnormal organ positioning, and fertility issues, resulting from defects in the action of cilia - microscopic, hair-like structures that line the airways, reproductive system, and other parts of the body. Mutations in the CCDC114 gene disrupt the normal function and structure of cilia, leading to the symptoms associated with PCD.
This test is crucial for individuals showing symptoms suggestive of PCD, or those with a family history of the condition, as it provides a definitive diagnosis by identifying mutations in the CCDC114 gene. Early and accurate diagnosis is essential for managing symptoms, improving quality of life, and providing genetic counseling.
The test is priced at 4400 AED and is conducted at DNA Labs UAE, a facility known for its advanced genetic testing services. The process involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed in the lab to detect any genetic abnormalities in the CCDC114 gene. Results from this test can guide treatment decisions and help in the planning of future family health.
The ARMC4 Gene Primary Ciliary Dyskinesia Type 23 Genetic Test is a specialized diagnostic examination conducted to identify mutations in the ARMC4 gene, which are associated with Primary Ciliary Dyskinesia (PCD) Type 23. PCD is a rare genetic disorder characterized by chronic respiratory tract infections, abnormal organ positioning, and fertility issues, stemming from defects in the structure and function of cilia. The ARMC4 gene plays a crucial role in the development and function of cilia, and mutations in this gene can lead to the manifestation of PCD symptoms.
This genetic test is vital for individuals showing symptoms of PCD or those with a family history of the condition, as it can provide a definitive diagnosis. By pinpointing the specific mutation within the ARMC4 gene, healthcare providers can better understand the condition's progression, tailor treatments to manage symptoms more effectively, and offer genetic counseling for affected families.
The test is available at DNA Labs UAE, a leading facility in genetic diagnostics and research. The cost of the ARMC4 Gene Primary Ciliary Dyskinesia Type 23 Genetic Test is 4400 AED. Conducting the test in such a specialized lab ensures accuracy and reliability in the results, offering crucial information for managing and understanding this rare genetic disorder.
The RSPH1 Gene Primary Ciliary Dyskinesia Type 24 Genetic Test is a specialized diagnostic examination offered by DNA Labs UAE, aimed at detecting mutations in the RSPH1 gene, which are implicated in Primary Ciliary Dyskinesia (PCD) type 24. PCD is a rare genetic disorder characterized by chronic respiratory tract infections, abnormal organ positioning, and fertility issues, resulting from defects in the structure and function of cilia. The RSPH1 gene plays a crucial role in the development and operation of these cilia. Identifying mutations in this gene can confirm a diagnosis of PCD type 24, enabling targeted management and treatment strategies for affected individuals. The test is priced at 4400 AED and involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory to identify any genetic alterations in the RSPH1 gene. This test is crucial for families with a history of PCD, as it can aid in early diagnosis and intervention, potentially improving the quality of life for those affected by the condition.
The DYX1C1 Gene Primary Ciliary Dyskinesia Type 25 Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to identify mutations in the DYX1C1 gene that are associated with Primary Ciliary Dyskinesia (PCD) Type 25. PCD is a rare genetic disorder characterized by chronic respiratory tract infections, abnormal organ positioning, and infertility due to defects in the structure and function of cilia. The DYX1C1 gene plays a crucial role in the development and function of cilia, and mutations in this gene can lead to the symptoms observed in PCD Type 25.
This genetic test is essential for the accurate diagnosis of PCD Type 25, enabling healthcare providers to tailor treatments and management strategies to the specific needs of the patient. Early diagnosis and intervention can significantly improve the quality of life for individuals with this condition. The test involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in the laboratory for the presence of mutations in the DYX1C1 gene.
At DNA Labs UAE, the cost of the DYX1C1 Gene Primary Ciliary Dyskinesia Type 25 Genetic Test is 4400 AED. The test is conducted with the utmost care and precision, ensuring reliable results for patients and their families. With advanced genetic testing capabilities, DNA Labs UAE is at the forefront of providing critical diagnostic services that contribute to the effective management of genetic disorders like Primary Ciliary Dyskinesia.
The CFAP298 gene is associated with a condition known as Primary Ciliary Dyskinesia (PCD), specifically identified as Type 26. This genetic disorder affects the cilia, which are tiny, hair-like structures that line the airways, reproductive system, and other parts of the body. In PCD, the cilia's structure or function is impaired, leading to various clinical manifestations including respiratory tract infections, reduced fertility, and sometimes situs inversus (a condition where the major visceral organs are reversed or mirrored from their normal positions).
A genetic test for CFAP298, indicative of Primary Ciliary Dyskinesia Type 26, is available at DNA Labs UAE. This test is designed to identify mutations in the CFAP298 gene, providing essential information for diagnosis, treatment planning, and genetic counseling. The cost of the test is 4400 AED, which reflects the specialized nature of the testing and the valuable insights it offers for affected individuals and their families. By confirming a diagnosis of PCD Type 26, this test can guide medical management and help in understanding the prognosis of the condition.
The CCDC65 gene is associated with Primary Ciliary Dyskinesia (PCD) Type 27, a genetic disorder that affects the function of cilia, the tiny hair-like structures that line the airways, reproductive system, and other parts of the body. Mutations in the CCDC65 gene disrupt the normal structure and function of cilia, leading to symptoms such as chronic respiratory infections, infertility, and problems with organ placement in the body.
To diagnose this specific type of PCD, genetic testing for mutations in the CCDC65 gene is available. DNA Labs UAE offers a comprehensive genetic test for CCDC65 gene mutations, helping in the diagnosis of Primary Ciliary Dyskinesia Type 27. The test is crucial for affected individuals and their families for several reasons, including confirming the diagnosis, understanding the risk of passing the condition to future generations, and guiding treatment and management decisions.
The cost of the CCDC65 gene Primary Ciliary Dyskinesia Type 27 genetic test at DNA Labs UAE is 4400 AED. This investment can provide essential information for affected individuals and their healthcare providers, enabling more personalized and effective care plans.
The SPAG1 Gene Primary Ciliary Dyskinesia Type 28 Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE. Priced at 4400 AED, this test specifically targets the SPAG1 gene, mutations in which are known to cause Primary Ciliary Dyskinesia (PCD) Type 28. PCD is a rare genetic disorder characterized by chronic respiratory tract infections, abnormal organ positioning, and fertility issues, resulting from defective cilia function. The SPAG1 gene plays a crucial role in the proper formation and function of cilia, and its mutations can lead to the symptoms associated with PCD.
The test is conducted using a sample of the patient's DNA, obtained through a non-invasive method such as a blood draw or a cheek swab. It is designed to detect specific genetic mutations in the SPAG1 gene, providing a definitive diagnosis of PCD Type 28. This information is crucial for guiding treatment decisions, managing symptoms, and offering genetic counseling to affected families.
DNA Labs UAE, a leading provider of genetic testing services in the region, ensures that the test is conducted with the highest standards of accuracy and confidentiality. The test is recommended for individuals exhibiting symptoms of PCD or those with a family history of the condition, aiming to offer them a clear understanding of their genetic status and how it might impact their health and lifestyle.
The "CCNO Gene Primary Ciliary Dyskinesia Type 29 Genetic Test" is a specialized diagnostic procedure offered at DNA Labs UAE, designed to identify mutations in the CCNO gene, which are associated with Primary Ciliary Dyskinesia (PCD) Type 29. PCD is a rare genetic disorder that affects the cilia, leading to respiratory system abnormalities, fertility issues, and other complications. The CCNO gene plays a crucial role in the development and function of cilia, and mutations in this gene can disrupt ciliary function, resulting in the symptoms observed in PCD.
This test is critical for individuals suspected of having PCD Type 29 based on clinical symptoms or family history, as an accurate diagnosis can guide treatment and management decisions. The procedure involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed for specific genetic mutations in the CCNO gene.
The cost of the test is 4400 AED, reflecting the specialized nature of the genetic analysis and the expertise required to interpret the results. Conducted at DNA Labs UAE, a facility known for its advanced genetic testing services, patients can expect a high standard of accuracy and reliability in their test results, which are essential for diagnosing this complex condition and potentially guiding family planning decisions for affected individuals or families.
The DNAH5 Gene Primary Ciliary Dyskinesia Type 3 Genetic Test is a specialized diagnostic procedure aimed at identifying mutations in the DNAH5 gene, which are associated with Primary Ciliary Dyskinesia (PCD) Type 3. PCD is a rare, genetic disorder that impairs the function of cilia, the microscopic, hair-like structures that line the respiratory tract, ears, and sinuses. Individuals with PCD typically experience chronic respiratory tract infections, reduced fertility, and, in some cases, organ laterality defects.
The DNAH5 gene plays a crucial role in the development and function of cilia. Mutations in this gene can lead to the structural and functional abnormalities characteristic of PCD. By specifically analyzing the DNAH5 gene, this test can confirm a diagnosis of PCD Type 3, allowing for appropriate clinical management and genetic counseling.
Performed at DNA Labs UAE, a leading facility in genetic testing, the test offers a comprehensive analysis of the DNAH5 gene. The cost of the test is 4400 AED. The test process involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed in the laboratory for the presence of mutations in the DNAH5 gene. Results from this test can provide valuable information for affected individuals and their families regarding the condition, its progression, and potential treatment options.
The HYDIN gene primary ciliary dyskinesia type 5 genetic test is a specialized diagnostic procedure designed to identify mutations in the HYDIN gene, which are associated with primary ciliary dyskinesia (PCD) type 5. PCD is a rare, inherited disorder that affects the cilia, leading to chronic respiratory tract infections, abnormal organ positioning, and fertility issues. The HYDIN gene plays a crucial role in the development and function of cilia, and mutations in this gene can disrupt ciliary motion, resulting in the symptoms of PCD.
This genetic test is crucial for early diagnosis and management of the condition, allowing for tailored treatments that can improve the quality of life for affected individuals. The test involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed in a laboratory for the presence of specific mutations in the HYDIN gene.
In the UAE, this test is available at DNA Labs UAE, a leading provider of genetic testing services in the region. The cost of the HYDIN gene primary ciliary dyskinesia type 5 genetic test at DNA Labs UAE is 4400 AED. This cost covers the collection of the sample, the genetic analysis, and a comprehensive report of the findings, which can be used by healthcare professionals to guide treatment and management decisions for patients with PCD.
